PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11404490-1 2001 The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC). Fluorouracil 139-153 colony stimulating factor 3 Homo sapiens 172-209 17716984-0 2007 A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Fluorouracil 88-102 colony stimulating factor 3 Homo sapiens 109-114 17716984-8 2007 CONCLUSION: A dose-intense and dose-dense regimen of cyclophosphamide, epirubicin and 5-fluorouracil was delivered with G-CSF without apparent increase in acute toxicity. Fluorouracil 86-100 colony stimulating factor 3 Homo sapiens 120-125 17453364-2 2007 A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity. Fluorouracil 130-144 colony stimulating factor 3 Homo sapiens 74-111 17453364-2 2007 A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity. Fluorouracil 130-144 colony stimulating factor 3 Homo sapiens 113-118 16520664-14 2006 Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active. Fluorouracil 117-121 colony stimulating factor 3 Homo sapiens 144-149 12123334-2 2002 Theoretically, this approach could be hazardous with infusional 5-fluorouracil (5-FU) chemotherapy, since G-CSF-stimulated neutrophil proliferation would be occurring in the face of continuous S-phase active 5-FU. Fluorouracil 64-78 colony stimulating factor 3 Homo sapiens 106-111 12123334-2 2002 Theoretically, this approach could be hazardous with infusional 5-fluorouracil (5-FU) chemotherapy, since G-CSF-stimulated neutrophil proliferation would be occurring in the face of continuous S-phase active 5-FU. Fluorouracil 80-84 colony stimulating factor 3 Homo sapiens 106-111 11404490-1 2001 The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC). Fluorouracil 155-159 colony stimulating factor 3 Homo sapiens 172-209 9636831-4 1998 The first 89 consecutive patients who have received nine courses q three weeks of individually dose-escalated and G-CSF (filgrastim)-supported FEC (5-fluorouracil (5-FU), epirubicin, and cyclophosphamide) therapy given with ciprofloxacin prophylaxis were included in this analysis. Fluorouracil 148-162 colony stimulating factor 3 Homo sapiens 114-119 11304774-1 2001 PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients. Fluorouracil 90-102 colony stimulating factor 3 Homo sapiens 150-187 9845529-5 1998 hG-CSF also had stimulatory effects on the formation of blast cell colonies in cultures using 5-fluorouracil-resistant hematopoietic progenitors and clone-sorted Lin-c-Kit+Sca-1(+) primitive hematopoietic cells. Fluorouracil 94-108 colony stimulating factor 3 Homo sapiens 0-6 9662268-6 1998 We evaluated 5-FU-treated human CD34+ PBSC proliferation in cultures with Epo, G-CSF, and IL-3, in the presence or absence of IL-12. Fluorouracil 13-17 colony stimulating factor 3 Homo sapiens 79-84 9662268-8 1998 However, in cultures of 5-FU-treated human CD34+ cells, the most efficient combination was IL-3 + Epo + G-CSF + Accessory cells (CD34-). Fluorouracil 24-28 colony stimulating factor 3 Homo sapiens 104-109 7538704-0 1995 Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF. Fluorouracil 73-87 colony stimulating factor 3 Homo sapiens 167-172 8742097-1 1996 It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg. Fluorouracil 257-271 colony stimulating factor 3 Homo sapiens 47-84 8742097-1 1996 It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg. Fluorouracil 257-271 colony stimulating factor 3 Homo sapiens 86-91 9217040-0 1997 Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Fluorouracil 40-54 colony stimulating factor 3 Homo sapiens 88-125 7525886-17 1994 CONCLUSION: The addition of cisplatin to 5-FU, HU, and concomitant radiotherapy is feasible using G-CSF. Fluorouracil 41-45 colony stimulating factor 3 Homo sapiens 98-103 3491641-0 1987 Effect of human recombinant granulocyte colony-stimulating factor on hematopoietic injury in mice induced by 5-fluorouracil. Fluorouracil 109-123 colony stimulating factor 3 Homo sapiens 28-65 29948238-1 2018 BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial. Fluorouracil 185-199 colony stimulating factor 3 Homo sapiens 49-86 29948238-1 2018 BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial. Fluorouracil 185-199 colony stimulating factor 3 Homo sapiens 88-93 29086459-9 2018 EGF increased G-CSF receptor (G-CSFR) expression following 5-FU. Fluorouracil 59-63 colony stimulating factor 3 Homo sapiens 14-19 24821366-0 2014 Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Fluorouracil 123-137 colony stimulating factor 3 Homo sapiens 29-34 24595405-2 2014 PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel). Fluorouracil 186-198 colony stimulating factor 3 Homo sapiens 34-71 24595405-2 2014 PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel). Fluorouracil 186-198 colony stimulating factor 3 Homo sapiens 73-78 23749899-8 2013 Under treatment with low concentrations of 5-fluorouracil and cisplatin, all examined cell lines showed an increasing secretion of the cytokines IL-6 and G-CSF. Fluorouracil 43-57 colony stimulating factor 3 Homo sapiens 154-159 7683729-0 1993 Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression? Fluorouracil 65-77 colony stimulating factor 3 Homo sapiens 0-37 1280628-1 1992 A comparison with recombinant human granulocyte colony-stimulating factor in 5-fluorouracil-treated mice. Fluorouracil 77-91 colony stimulating factor 3 Homo sapiens 36-73 2473792-3 1989 Cultures of unseparated bone marrow, harvested from patients four to six days after administration of 5-fluorouracil (5-FU), resulted in additive GM colony formation with GM-CSF plus G-CSF, GM-CSF plus IL-3, and G-CSF plus IL-3. Fluorouracil 118-122 colony stimulating factor 3 Homo sapiens 212-217 3499607-3 1987 When bone marrow cells from 5-fluorouracil-treated mice were cultured in suspension for 7 days with recombinant human IL-1 alpha and/or G-CSF, it was found that the two factors synergized to enhance recovery of myelopoietic cells and colony-forming cells of both high and low proliferative potential. Fluorouracil 28-42 colony stimulating factor 3 Homo sapiens 136-141 3499607-6 1987 Daily administration of recombinant human G-CSF or recombinant human IL-1 alpha accelerated recovery of stem cells, progenitor cells, and blood neutrophils by up to 4 days in 5-fluorouracil-treated C3H/HeJ and B6D2F1 mice. Fluorouracil 175-189 colony stimulating factor 3 Homo sapiens 42-47 34040446-10 2021 There was an inverse relationship between the frequency of G-CSF use and the RDI of continuous infusion 5FU, r=-0.26 (p<0.001). Fluorouracil 104-107 colony stimulating factor 3 Homo sapiens 59-64 33147611-0 2021 A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. Fluorouracil 135-149 colony stimulating factor 3 Homo sapiens 34-71 33147611-1 2021 BACKGROUND: An exploratory study was designed to evaluate the efficacy of granulocyte colony stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer. Fluorouracil 176-190 colony stimulating factor 3 Homo sapiens 74-111 33147611-12 2021 CONCLUSIONS: Granulocyte colony stimulating factor support including secondary prophylactic usage may be feasible for maintaining the intensity of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer. Fluorouracil 172-186 colony stimulating factor 3 Homo sapiens 13-50 28011495-8 2017 Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l. Fluorouracil 180-194 colony stimulating factor 3 Homo sapiens 0-37 28011495-8 2017 Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l. Fluorouracil 180-194 colony stimulating factor 3 Homo sapiens 39-44